Madrid

• A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) o … Ended
  2023-507143-11-00 5 2017-11-08 Precancerous form of blood cancer in the bone marrow
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 5 2017-10-27 Advanced or Metastatic Renal Cell Carcinoma
• A multicenter, open-label, randomized study with single-arm extension period to assess the pharmacokinetics, safety and efficacy of macitent … Ended
  2023-509845-10-00 5 2017-10-02 Pediatric pulmonary arterial hypertension
• A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended
  2023-508757-75-00 5 2017-09-18 Stage IV Non-Small Cell Lung Cancer (NSCLC)
• Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid … Ended
  2024-511916-25-00 7 2017-09-04 Advanced Solid Tumors
• This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body a … Ended
  2023-509969-20-00 1 2017-07-24 Part C: advanced or unresectable STs (Spain only)
• A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors Ended
  2023-508925-29-00 1 2017-06-29 Advanced solid tumors
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma
• CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended
  2022-501784-40-00 5 2017-05-26 Untreated Unresectable or Metastatic Urothelial Cancer
• Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER … Ended
  2024-514999-41-00 4 2017-04-28 HER2 negative metastatic breast cancer (MBC) with nervous system invol
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung … Ended
  2022-501360-18-00 5 2017-03-15 Early Stage Non-Small Cell Lung Cancer (NSCLC)
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended
  2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
• A trial of BMS-986012 in combination with chemotherapy for small cell lung cancer Ended
  2024-511824-15-00 9 2016-10-18 Extensive-Stage Small Cell Lung Cancer
• Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended
  2023-507294-18-00 5 2016-09-16 Metastatic renal cell carcinoma
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended
  2023-508010-42-00 5 2016-09-14 Homologous recombination deficiency advanced ovarian cancer
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended
  2024-512003-39-00 4 2016-07-18 Lung Cancer
• "A study to learn how well the drug larotrectinib works in adults with different solid cancers with a change in the genes called NTRK fusion … Ended
  2022-502667-38-00 4 2016-06-20 Solid tumors harboring NTRK fusion
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patien … Ended
  2024-515394-10-00 9 2016-04-26 Selected Advanced Solid Tumors
• Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended
  2022-502526-41-00 4 2016-03-15 Non-Muscle Invasive Bladder Cancer (NMIBC)
• Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg … Ended
  2024-516132-10-00 4 2016-02-05 Metastatic breast cancer

Showing 3,457–3,480 of 3,550 trials